Comparison of Effects of Propofol Combined with Different Doses of Esketamine for ECT in the Treatment of Depression: A Randomized Controlled Trial Protocol.
Xuemeng Chen, Rui Zhou, Lan Lan, Ling Zhu, Cheng Chen, Xianjie Zhang, Jia Han, Leqiang Xia
Neuropsychiatric Disease and Treatment 2024 DOI: 10.2147/NDT.S463028 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Double-blind Peer reviewed |
|---|---|
| Sample size | 111 |
| Population | Patients scheduled for electroconvulsive therapy |
| Interventions | Propofol Esketamine |
| Dose | propofol 1 mg/kg; propofol 0.5 mg/kg plus esketamine 0.5 mg/kg; propofol 0.75 mg/kg plus esketamine 0.25 mg/kg |
| Topics | Depression Esketamine |
| Keywords | Curative effect Electroconvulsive therapy Depression therapy Electroconvulsive treatment Esketamine research Mental health treatment Psychiatric medicine |
| Citations | 4 |
| Key findings | Combining different doses of esketamine with propofol for ECT anesthesia may offer advantages over propofol alone, but specific results are not yet reported. |
Abstract
Major depressive disorder (MDD) is a common mood disorder. Electroconvulsive therapy (ECT) has a significant effect on treatment-resistant MDD. Esketamine may have potential advantages in improving the efficacy of ECT, and the strong affinity of this compound for NMDAR renders it a viable therapeutic option for the management of depression. This study aims to compare the effects of different doses of esketamine combined with propofol anesthesia versus propofol anesthesia alone in ECT, aiming to provide further insights for optimizing ECT and enhancing comprehensive treatment outcomes for depression. This study was a prospective, randomized, controlled, double-blind trial involving subjects and evaluators. One hundred eleven patients scheduled for ECT were randomly assigned to three groups. In Group P, propofol at 1mg/kg was administered intravenously. In Group P+E, propofol at a dosage of 0.5mg/kg and esketamine at a dosage of 0.5mg/kg was administered intravenously. Patients in Group P+SE received propofol at a dosage of 0.75mg/kg and esketamine at a dosage of 0.25mg/kg. The same anesthesia protocol was used for the same patient until the end of the last treatment. The primary outcome measures were the Hamilton depression scale (HAMD) and the Patient Health Questionnaire-9 (PHQ-9), the Columbia-Suicide Severity Rating Scale (C-SSRS), and the Digit symbol substitution test (DSST). Secondary outcomes included length of hospital stay, readmission rate, hemodynamic status, recovery, and adverse events. This study aimed to compare the effects of propofol combined with different doses of esketamine for ECT. The results may provide a better choice for ECT anesthesia.
Comparable studies
Other randomized controlled trials on esketamine for depression, most cited first.